Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.67 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.67 |
| ▸ | IKZF1 | Q13422 | 3/20 | 0.67 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.67 |
| ▸ | BRD4 | O60885 | 1/20 | 0.67 |
| ▸ | TNF | P01375 | 1/20 | 0.67 |
| ▸ | IL1B | P01584 | 1/20 | 0.67 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.48 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17724153 | 1.00 | CRBN (0.67) | CRBNDDB1IKZF1IKZF3BRD4 | |
| SCHEMBL17724152 | 1.00 | CRBN (0.67) | CRBNDDB1IKZF1IKZF3BRD4 | |
| SCHEMBL24294412 | 0.89 | CRBN (0.58) | CRBNDDB1IKZF1IKZF3BRD4 | |
| SCHEMBL24817876 | 0.86 | CRBN (0.66) | CRBNDDB1IKZF1IKZF3BRD4 | |
| SCHEMBL30270923 | 0.85 | CRBN (0.55) | CRBNDDB1IKZF1IKZF3BRD4 | |
| SCHEMBL19451306 | 0.85 | CRBN (0.55) | CRBNDDB1IKZF1IKZF3BRD4 | |
| SCHEMBL30304165 | 0.85 | CRBN (0.67) | CRBNDDB1IKZF1IKZF3BRD4 | |
| SCHEMBL25010333 | 0.85 | CRBN (0.55) | CRBNDDB1IKZF1IKZF3BRD4 | |
| SCHEMBL21634456 | 0.85 | CRBN (0.55) | CRBNDDB1IKZF1IKZF3BRD4 | |
| SCHEMBL26102151 | 0.85 | CRBN (0.67) | CRBNDDB1IKZF1IKZF3BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023074780-A1 | THERAPEUTIC AGENT COMPOSITION | 国立大学法人愛媛大学 | 2023-05-04 | — | — | WO | disclosed |
| US-11505560-B2 | Heterobifunctional compounds with improved specificity | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| US-20210284657-A1 | FUSED 1,4-OXAZEPINES AS BET PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2021-09-16 | — | — | US | disclosed |
| EP-3527210-B1 | COMBINED COMPOSITION COMPRISING A BENZOHETEROCYCLIC COMPOUND AND AN ANDROGEN RECEPTOR PATHWAY MODULATOR AND USES THEREOF | KANGPU BIOPHARMACEUTICALS LTD (CN) | 2021-06-09 | — | — | EP | disclosed |
| US-20210130368-A1 | HETEROBIFUNCTIONAL COMPOUNDS WITH IMPROVED SPECIFICITY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-06 | — | — | US | disclosed |
| US-20210130368-A1 | HETEROBIFUNCTIONAL COMPOUNDS WITH IMPROVED SPECIFICITY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-06 | — | — | US | disclosed |
| US-10933059-B2 | Combination, application thereof and treatment method | KANGPU BIOPHARMACEUTICALS. LTD. (CN) | 2021-03-02 | — | — | US | disclosed |
| EP-3214081-B1 | ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | KANGPU BIOPHARMACEUTICALS LTD (CN) | 2020-07-08 | — | — | EP | disclosed |
| EP-3676268-A1 | HETEROBIFUNCTIONAL COMPOUNDS WITH IMPROVED SPECIFICITYFOR THE BROMODOMAIN OF BRD4 | Dana-Farber Cancer Institute, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| EP-3214081-B1 | ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | KANGPU BIOPHARMACEUTICALS LTD (CN) | 2020-07-08 | — | — | EP | disclosed |
| US-10017492-B2 | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2018-07-10 | — | — | US | disclosed |
| US-10017492-B2 | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2018-07-10 | — | — | US | disclosed |
| WO-2018052945-A1 | FUSED 1,4-OXAZEPINES AS BET PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-03-22 | — | — | WO | disclosed |
| US-20170313676-A1 | ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20170313676-A1 | ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20170313676-A1 | ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| EP-3214081-A1 | ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Kangpu Biopharmaceuticals, Ltd. (CN) | 2017-09-06 | — | — | EP | disclosed |
| EP-3214081-A1 | ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Kangpu Biopharmaceuticals, Ltd. (CN) | 2017-09-06 | — | — | EP | disclosed |
| CN-105566290-A | Isoindoline derivative, intermediate thereof, preparation method, pharmaceutical composition and application | KANGPU BIOMEDICAL TECH (SHANGHAI) CO LTD | 2016-05-11 | — | — | CN | disclosed |
| WO-2016065980-A1 | ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 康朴生物医药技术（上海）有限公司 | 2016-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130368-A1 | HETEROBIFUNCTIONAL COMPOUNDS WITH IMPROVED SPECIFICITY | MDM2, STUB1, UBE3C | CRBN 113/4885DDB1 249/4885IKZF1 507/4885 |
| US-10933059-B2 | Combination, application thereof and treatment method | CYP21A2, CYP17A1, NR5A1 | CRBN 4314/4885DDB1 4453/4885IKZF1 3686/4885 |
| US-10017492-B2 | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof | IL2, IL1B, IL5 | CRBN 3765/4885DDB1 3019/4885IKZF1 96/4885 |
| US-20170313676-A1 | ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | IL2, IL1B, IL5 | CRBN 3765/4885DDB1 3019/4885IKZF1 96/4885 |
| US-11505560-B2 | Heterobifunctional compounds with improved specificity | MDM2, STUB1, UBE3C | CRBN 113/4885DDB1 249/4885IKZF1 507/4885 |
| US-20210284657-A1 | FUSED 1,4-OXAZEPINES AS BET PROTEIN DEGRADERS | BRD4, BET1, BRD1 | CRBN 179/4885DDB1 425/4885IKZF1 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.